SCHEMBL6165060

SCHEMBL6165060

CC(C)(C)OC(=O)CC(=O)c1cccc(-c2cocn2)c1

nearest known ligand 0.41

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
SCN9A Q15858 2/20 0.41
GPR119 Q8TDV5 1/20 0.41
EGFR P00533 1/20 0.38
ERCC5 P28715 2/20 0.37
FEN1 P39748 2/20 0.37
AR P10275 1/20 0.36
IMPDH2 P12268 1/20 0.36
IMPDH1 P20839 1/20 0.36
ACACB O00763 1/20 0.36
ACACA Q13085 1/20 0.36
P2RY12 Q9H244 1/20 0.35
HDAC4 P56524 1/20 0.35
RXRA P19793 1/20 0.34
NR1H2 P55055 1/20 0.34
NR1H3 Q13133 1/20 0.34
MAPT P10636 2/20 0.34
MAPK1 P28482 1/20 0.34
USP30 Q70CQ3 1/20 0.34
MEN1 O00255 1/20 0.34
NPC1 O15118 1/20 0.34

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL5562300 0.81 KAT6A (0.44) SCN9AERCC5FEN1ACACBACACA
SCHEMBL5558795 0.81 KAT6A (0.41) ERCC5FEN1ACACBACACAMAPT
SCHEMBL5557326 0.80 AAK1 (0.48) ACACBACACAMAPTMAPK1
SCHEMBL6167491 0.80 MAPT (0.45) SCN9AGPR119ERCC5FEN1MAPT
SCHEMBL5562095 0.80 ABL1 (0.48) ERCC5FEN1ACACBACACANPC1
SCHEMBL6167366 0.79 GABRA5 (0.38) ERCC5FEN1ACACBACACAMAPT
SCHEMBL6163222 0.79 KAT6A (0.47) SCN9AEGFRERCC5FEN1ACACB
SCHEMBL5559626 0.79 ROCK1 (0.41) GPR119ERCC5FEN1ACACBACACA
SCHEMBL5564018 0.79 AAK1 (0.48) ERCC5FEN1ACACBACACAMAPT
SCHEMBL5558020 0.78 GRM5 (0.41) ERCC5FEN1ACACBACACAP2RY12

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-1379511-B1 DIHYDRO-BENZO (b) (1, 4) DIAZEPIN-2-ONE DERIVATIVES AS MGLUR2 ANTAGONISTS II HOFFMANN LA ROCHE (CH) 2005-07-20 EP disclosed
EP-1379511-A1 DIHYDRO-BENZO (b) (1, 4) DIAZEPIN-2-ONE DERIVATIVES AS MGLUR2 ANTAGONISTS II F. HOFFMANN-LA ROCHE AG (CH) 2004-01-14 EP disclosed
US-6544985-B2 For therapy of acute and/or chronic neurological disorders such as psychosis, schizophrenia, Alzheimer's disease, cognitive disorders and memory deficits HOFFMAN-LA ROCHE INC. 2003-04-08 US disclosed
US-20020193367-A1 Dihydro-benzo [b] [1,4] diazepin-2-one derivatives F. HOFFMAN-LA ROCHE AG A SWISS COMPANY (CH) 2002-12-19 US disclosed
WO-2002083652-A1 DIHYDRO-BENZO [b] [1, 4] DIAZEPIN-2-ONE DERIVATIVES AS MGLUR2 ANTAGONISTS II F. HOFFMANN-LA ROCHE AG (CH) 2002-10-24 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20020193367-A1 Dihydro-benzo [b] [1,4] diazepin-2-one derivatives CYP1B1, GRIN2B, BDKRB1 SCN9A 846/4885GPR119 1166/4885EGFR 4810/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.